Women had a lower probability of receiving any disease-modifying treatment (DMT) and were even less likely to get ...

Starting high-efficacy monoclonal antibody therapy during childhood reduced long-term disability in pediatric-onset multiple ...

Sanofi’s experimental drug for a form of multiple sclerosis delayed the progression of disability by nearly a third, ...

Rutgers Health researchers will enroll primary or secondary progressive multiple sclerosis (p-MS) patients to see if an ...

Researchers have identified biomarkers that can predict disease progression in multiple sclerosis, which could lead to the ...

Key biomarkers identified can now predict disability progression in multiple sclerosis, offering potential for more ...

A new study reveals how gender disparities cause therapeutic inertia in MS treatment for women, highlighting delays and ...

New research presented today at European Committee for Treatment and Research in Multiple Sclerosis 2024 reveals that ...

A study has revealed significant therapeutic inertia in the treatment of women with multiple sclerosis (MS), highlighting gender disparities that could impact long-term health outcomes for women of ...

Available disease-modifying therapies can prevent relapses and relapse-associated worsening in people with multiple sclerosis by targeting autoimmunity through various mechanisms. However, these ...

Tolebrutinib delayed the onset of disability progression by 31% for patients with a type of the disease called non-relapsing ...

A study presented at ECTRIMS 2024 has identified critical biomarkers that can predict disability worsening in multiple ...